𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Sa1884 Infliximab Versus Immunomodulator as First Maintenance Therapy in Children With Crohn Disease

✍ Scribed by Markowitz, James; Evans, Jonathan; Pfefferkorn, Marian D.; Griffiths, Anne M.; Keljo, David J.; Mack, David R.; Carvalho, Ryan; Leleiko, Neal S.; Otley, Anthony R.; Rosh, Joel R.; Stephens, Michael C.; Saeed, Shehzad A.; Ashai-Khan, Farhat N.; Bousvaros, Athos; Kay, Marsha H.; Oliva-Hemker, Maria; Grossman, Andrew B.; Sudel, Boris; Kappelman, Michael; Dimmitt, Reed A.; Langton, Christine R.; Hyams, Jeffrey S.


Book ID
122159187
Publisher
Elsevier Science
Year
2012
Tongue
English
Weight
60 KB
Volume
142
Category
Article
ISSN
0016-5085

No coin nor oath required. For personal study only.


πŸ“œ SIMILAR VOLUMES


Long-term outcome of maintenance inflixi
✍ Jeffrey S. Hyams; Trudy Lerer; Anne Griffiths; Marian Pfefferkorn; Subra Kugatha πŸ“‚ Article πŸ“… 2009 πŸ› John Wiley and Sons 🌐 English βš– 218 KB πŸ‘ 2 views

Background: Infliximab therapy has short-term benefits in children with moderate-to-severe Crohn's disease (CD). We assessed the long-term outcome of infliximab maintenance therapy in children with CD. ## Methods: We performed a multicenter cohort study of 729 pediatric patients with CD enrolled i